Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WATERTOWN, MASS., MARCH 10, 2026 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT DATA FROM ITS KT-621 BROADEN PHASE 1B CLINICAL TRIAL IN PATIENTS WITH ATOPIC DERMATITIS WILL BE PRESENTED IN A LATE-BREAKING ORAL SESSION AT THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) 2026 ANNUAL MEETING. THE MEETING WILL BE HELD MARCH 27-31, 2026, IN DENVER, CO. KYMERA WILL ALSO HOST A BOOTH (#3551) IN THE CONGRESS EXHIBIT HALL.

KYMERA THERAPEUTICS ANNOUNCES LATE-BREAKING ORAL PRESENTATION OF KT-621 PHASE 1B DATA AT THE AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETING

KT-621 BROADEN2 PHASE 2B TRIAL IN AD ONGOING, WITH DATA EXPECTED BY MID-2027 KT-621 BREADTH PHASE 2B TRIAL IN ASTHMA INITIATED, WITH DATA EXPECTED IN LATE-2027 KT-579 PHASE 1 HV CLINICAL TRIAL EXPECTED TO START IN 1Q26, WITH DATA EXPECTED IN 2H26 ADVANCING AT LEAST ONE NEW DEVELOPMENT CANDIDATE TOWARDS IND FOR A FIRST-IN-CLASS, ORAL IMMUNOLOGY PROGRAM IN 2026 WELL-CAPITALIZED WITH $1.6 BILLION 1 IN CASH AND RUNWAY INTO 2029 KYMERA TO PRESENT ITS 2026 OBJECTIVES AT THE J.P. MORGAN 44 TH ANNUAL HEALTHCARE CONFERENCE TODAY AT 9:00 A.M.

KYMERA THERAPEUTICS OUTLINES KEY 2026 OBJECTIVES AND STRATEGY TO ADVANCE INDUSTRY LEADING PORTFOLIO OF ORAL IMMUNOLOGY PROGRAMS

WATERTOWN, MASS., DEC. 11, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS UPSIZED UNDERWRITTEN PUBLIC OFFERING OF $602.0 MILLION OF SHARES OF ITS COMMON STOCK. KYMERA SOLD AND ISSUED 8,050,000 SHARES OF ITS COMMON STOCK, WHICH INCLUDES 1,050,000 SHARES SOLD AND ISSUED UPON THE FULL EXERCISE BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES OF COMMON STOCK. THE SHARES OF COMMON STOCK WERE SOLD AT A PUBLIC OFFERING PRICE OF $86.00 PER SHARE. THE GROSS PROCEEDS TO KYMERA FROM THE OFFERING WERE APPROXIMATELY $692.3 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES PAYABLE BY KYMERA.

KYMERA THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED $602 MILLION PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

WATERTOWN, MASS., DEC. 08, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $500.0 MILLION OF SHARES OF ITS COMMON STOCK. ALL OF THE SHARES OF COMMON STOCK TO BE SOLD IN THIS OFFERING ARE BEING OFFERED BY KYMERA. IN ADDITION, KYMERA INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $75.0 MILLION OF SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE PER SHARE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

KYMERA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING

KT-621 ACHIEVED DEEP STAT6 DEGRADATION ACROSS BOTH THE 100 MG AND 200 MG DOSE GROUPS TESTED, WITH MEDIAN REDUCTIONS OF 94% AND 98% IN SKIN AND BLOOD, RESPECTIVELY, DEMONSTRATING STRONG TRANSLATION FROM HEALTHY VOLUNTEERS TO ATOPIC DERMATITIS (AD) PATIENTS

KYMERA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM BROADEN PHASE 1B CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER, IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

COMPANY TO HOST VIDEO CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON MONDAY, DECEMBER 8, 2025 WATERTOWN, MASS.

KYMERA THERAPEUTICS TO ANNOUNCE KT-621 BROADEN PHASE 1B ATOPIC DERMATITIS TRIAL RESULTS ON DECEMBER 8, 2025

DATA FROM THE KT-621 BROADEN2 PHASE 2B AD PATIENT TRIAL EXPECTED TO BE REPORTED BY MID-2027 KT-621 BREADTH PHASE 2B TRIAL IN ASTHMA ON TRACK TO INITIATE IN 1Q26 COMPLETED DOSING IN KT-621 BROADEN PHASE 1B AD TRIAL WITH DATA TO BE REPORTED IN DECEMBER 2025 WATERTOWN, MASS., NOV. 25, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT IT RECENTLY INITIATED DOSING IN ITS BROADEN2 PHASE 2B CLINICAL TRIAL EVALUATING KT-621, AN ORAL, HIGHLY SELECTIVE, POTENT DEGRADER OF STAT6, IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD).

KYMERA THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN BROADEN2 PHASE 2B ATOPIC DERMATITIS CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER

WATERTOWN, MASS., NOV. 24, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC.(NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN FIRESIDE CHATS AT THE FOLLOWING UPCOMING INVESTOR EVENTS:

KYMERA THERAPEUTICS TO PARTICIPATE IN UPCOMING DECEMBER INVESTOR CONFERENCES

WATERTOWN, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN FIRESIDE CHATS AT THE FOLLOWING UPCOMING INVESTOR EVENTS:

KYMERA THERAPEUTICS TO PARTICIPATE IN UPCOMING NOVEMBER INVESTOR CONFERENCES

WATERTOWN, MASS., OCT. 28, 2025 (GLOBE NEWSWIRE) -- KYMERA THERAPEUTICS, INC. (NASDAQ: KYMR), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ADVANCING A NEW CLASS OF ORAL SMALL MOLECULE DEGRADER MEDICINES FOR IMMUNOLOGICAL DISEASES, WILL REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON NOVEMBER 4, 2025. THE COMPANY WILL HOST A VIDEO CONFERENCE CALL AND WEBCAST AT 8:30 A.M. ET THAT DAY.

Kymera Therapeutics, Inc.

KYMR

Price

Financial Reports

No items found.

Press Releases

Kymera Therapeutics, Inc.

KYMR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

KYMR